Viktor Rotbain Curovic, Morten B Houlind, Marjolein Y A M Kroonen, Niels Jongs, Emilie H Zobel, Tine W Hansen, Juliette Tavenier, Jesper Eugen-Olsen, Gozewijn D Laverman, Adriaan Kooy, Frederik Persson, Peter Rossing, Hiddo J L Heerspink
AIM: To evaluate the effect of four different drug classes on soluble urokinase plasminogen activator receptor (suPAR), a biomarker active in multiple inflammatory processes and a risk factor for complications, in people with type 1 and type 2 diabetes. METHODS: We conducted post hoc analyses of a randomized, open-label, crossover trial including 26 adults with type 1 and 40 with type 2 diabetes with urinary albumin-creatinine ratio ≥30 and ≤500 mg/g assigned to 4-week treatments with telmisartan 80 mg, empagliflozin 10 mg, linagliptin 5 mg and baricitinib 2 mg, separated by 4-week washouts...
July 7, 2023: Diabetes, Obesity & Metabolism